Document is current
Any future updates will be listed below
-
Authors
Shah, Mithun Vinod https://orcid.org/0000-0002-5359-336X
Hung, Kevin https://orcid.org/0009-0001-9354-5864
Baranwal, Anmol https://orcid.org/0000-0002-3432-0489
Wechalekar, Gauri
Al-Kali, Aref https://orcid.org/0000-0002-0824-3715
Toop, Carla R.
Greipp, Patricia
Kutyna, Monika M.
Matin, Aasiya
Ladon, Dariusz
Saliba, Antoine https://orcid.org/0000-0001-5134-7336
Chen, Dong https://orcid.org/0000-0001-7627-9560
Begna, Kebede https://orcid.org/0000-0003-2730-8593
Brown, Anna https://orcid.org/0000-0002-9023-0138
Rud, Danielle
Litzow, Mark R.
Hogan, William J. https://orcid.org/0000-0002-5841-4105
Bardy, Peter
Badar, Talha https://orcid.org/0000-0003-1548-918X
Kumar, Sharad https://orcid.org/0000-0001-7126-9814
Yeung, David T.
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
Foran, James M. https://orcid.org/0000-0003-1673-1708
He, Rong https://orcid.org/0000-0001-6116-8163
Gangat, Naseema https://orcid.org/0000-0002-9104-6172
Hefazi, Mehrdad https://orcid.org/0000-0001-8860-3380
Scott, Hamish S. https://orcid.org/0000-0002-5813-631X
Arana Yi, Cecilia Y.
Alkhateeb, Hassan https://orcid.org/0000-0002-3609-8404
Mangaonkar, Abhishek A. https://orcid.org/0000-0003-2458-9887
Thomas, Daniel
Hahn, Christopher N. https://orcid.org/0000-0001-5105-2554
Orazi, Attilio https://orcid.org/0000-0002-1660-7013
Arber, Daniel A. https://orcid.org/0000-0002-2160-9689
Kok, Chung Hoow https://orcid.org/0000-0002-3181-7852
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
Hiwase, Devendra https://orcid.org/0000-0002-6666-3056
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (MRF1195517, GNT2007739)
Leukaemia Foundation
Clinician Career Development Award in Transplant Research Honoring Brigid Kiley
Leukemia and Lymphoma Society
CSL Centenary Fellowship
- License Information
-
More Information
Article History
Received: 27 December 2024
Revised: 9 April 2025
Accepted: 16 April 2025
First Online: 7 May 2025
Competing interests
: MVS declares research funding to the institution from AbbVie, Astellas, Celgene, KURA Oncology, and Marker Therapeutics. D.H. is a member of the board of directors or advisory committees of AbbVie and Novartis. A.A.K. provides research support to Novartis and Astex. M.P. is a member of the board of directors or advisory committees of Stemline Therapeutics and receives research funding from Kura Oncology. P.G. is a member of the advisory board of AbbVie. N.G. has served on the Advisory Board for Agio and DISC Medicine. The remaining authors declare no competing interests.
